<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570336</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-1027-01</org_study_id>
    <nct_id>NCT00570336</nct_id>
  </id_info>
  <brief_title>Study of CTS-1027 in Hepatitis C Patients</brief_title>
  <official_title>A Dose Response Study of CTS-1027 in Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conatus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Conatus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in
      patients with chronic HCV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response
      trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with
      chronic hepatitis C virus (HCV) infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events at each dose level</measure>
    <time_frame>4 to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose</measure>
    <time_frame>4-24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak and trough levels of CTS-1027 in plasma</measure>
    <time_frame>4 to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>2.5 milligram (mg) CTS-1027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg CTS-1027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg CTS-1027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg CTS-1027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg CTS-1027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg CTS-1027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg CTS-1027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg CTS-1027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTS-1027</intervention_name>
    <description>Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).</description>
    <arm_group_label>2.5 milligram (mg) CTS-1027</arm_group_label>
    <arm_group_label>5 mg CTS-1027</arm_group_label>
    <arm_group_label>10 mg CTS-1027</arm_group_label>
    <arm_group_label>30 mg CTS-1027</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients of minimum adult legal age (according to local laws for
             signing the informed consent document), able to provide written informed consent, and
             understand and comply with the requirements of the trial

          -  A history of chronic HCV infection

          -  Unsuccessful HCV treatment defined as one or more of the following criteria:

               1. Failure to achieve a virologic response during previous therapy, or

               2. Failure to tolerate therapy, or

               3. Failure to maintain a sustained virologic response, or

               4. In the opinion of the Principal Investigator, the patient is not a suitable
                  candidate for interferon based therapy

          -  Liver impairment, as defined by either aspartate aminotransferase (AST) and/or alanine
             aminotransferase (ALT) levels 1.5 - 7 x ULN on at least two occasions, seven or more
             days apart, during the baseline period

          -  Alpha-fetoprotein (AFP) &lt;= 50 ng/mL

          -  Hemoglobin &gt;= 10 g/dL, platelet count &gt;= 75 x 109/L, and white blood cell count &gt;= 1.5
             x 109/L

          -  Willingness to utilize adequate contraception (if female, evidenced by being
             postmenopausal for at least 6 months or using contraceptive pill; for both females and
             males, being surgically sterile, or using two forms of barrier contraception) from
             screening to at least one month after the completion of the trial.

        Exclusion Criteria:

          -  Decompensated or severe liver disease defined by one or more of the following
             criteria:

               1. Prior liver biopsy showing cirrhosis

               2. Prior liver biopsy showing bridging fibrosis (Metavir &gt;2 or Ishak &gt;3) more than 2
                  years ago in the absence of newer liver biopsy results

               3. Prothrombin time: 3 seconds &gt; control

               4. Total bilirubin &gt;= 1.5 x Upper limit of the normal range (ULN), or &gt; 3 x ULN for
                  unconjugated bilirubin

               5. Serum albumin below normal limits

               6. AST or ALT &gt; 7 x ULN during baseline period

               7. Evidence of portal hypertension including:

          -  Splenomegaly or evidence of portal hypertension (i.e., enlarged portal vein and
             varices) on ultrasound,

          -  Varices in esophagogastroduodenoscopy (EGD); or

          -  Ascites

          -  Hepatocellular carcinoma (HCC) or suspicion of HCC clinically or on ultrasound (or
             other imaging techniques)

          -  Known history or presence of human immunodeficiency virus (HIV) infection

          -  Co-infection with hepatitis B virus (HBV)

          -  If female: pregnant, lactating, or positive serum or urine pregnancy test

          -  Last baseline AST and ALT level prior to Day 1 of &lt; 1.5 x ULN

          -  Renal impairment (creatinine &gt; 1.5 x ULN) or hepatorenal syndrome

          -  Pancreatitis

          -  Hospitalization for liver disease within 60 days of screening

          -  Use of concomitant or prior drug therapy for HCV at screening, including the use of:

               1. drugs with presumed anti-HCV activity in the prior three months

               2. corticosteroids in the past 30 days

               3. potentially hepatotoxic drugs in the past 30 days (including alpha methyl-dopa,
                  sodium valproic acid, isoniazide, or nitrofurantoin)

          -  Use of illicit or drugs of abuse in the prior three months (allowed if medically
             prescribed or indicated)

          -  History of alcohol abuse within the past year

          -  History or presence of clinically concerning cardiac arrhythmias or prolongation of
             pre-dose QT or QTc interval of &gt; 450 milliseconds

          -  Other concomitant disease or condition likely to significantly decrease life
             expectancy (e.g., moderate to severe congestive heart failure) or any malignancy other
             than curatively treated skin cancer (basal cell or squamous cell carcinomas), unless
             adequately treated or in complete remission for ten or more years

          -  Any patient who has received any investigational drug or device within 30 days of
             dosing, or who is scheduled to receive another investigational drug or device during
             the course of this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Frank, MD</last_name>
    <role>Study Director</role>
    <affiliation>Conatus Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx VA Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants of Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Liver Therapies - Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VAMC - Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire Hospital DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <disposition_first_submitted>August 31, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 9, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 13, 2010</disposition_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>MiRa Huyghe</name_title>
    <organization>Conatus Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>HCV treatment failure</keyword>
  <keyword>Elevated aminotransferases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

